Bivalirudin vs Heparin in ECMO Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03707418 |
Recruitment Status :
Withdrawn
(unable to secure funding)
First Posted : October 16, 2018
Last Update Posted : January 19, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Extracorporeal Membrane Oxygenation Complication | Drug: Heparin Sodium Drug: Bivalirudin Injection [Angiomax] | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Study Comparing Bivalirudin vs Heparin in Patients With Extracorporeal Membrane Oxygenator (ECMO) Support |
Estimated Study Start Date : | April 2021 |
Estimated Primary Completion Date : | June 2021 |
Estimated Study Completion Date : | June 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Bivalirudin Injection (Angiomax)
This arm will receive intravenous Bivalirudin for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
|
Drug: Bivalirudin Injection [Angiomax]
Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels |
Active Comparator: Heparin Sodium
This arm will receive intravenous Heparin Sodium for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
|
Drug: Heparin Sodium
Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels |
- Number of heparin-induced thrombocytopenia (HIT) events [ Time Frame: 30 days ]This will be assessed by serum platelet factor 4 antibody level
- Number of Cross-overs between arms [ Time Frame: 30 days ]
This will be assessed by number of cross over of patients from one arm to the other anti-coagulation arm for any particular clinical reason.
Crossover patients will remain in the study and we will continue to collect protocol driven data. These patients will be analyzed separately from those with no cross-over.
- Number of circuit failures requiring a circuit exchange [ Time Frame: 30 days ]Will be determined by total number of circuit exchanges needed in ECMO circuit due to thrombosis. Circuit exchanges may be done due to lack of adequate gas exchange or increased resistance pre and post oxygenator >50mmHg, circuit thrombosis or failure requiring emergent decannulation
- Thrombotic events [ Time Frame: 30 days ]Collect number of thrombotic events, defined as any of the following events; embolic strokes, embolic end-organ ischemia, embolic ischemia to limbs, deep vein thrombosis or venous thromboembolism, Oxygenator effectiveness measured by resistance, Alveolar-arterial oxygen gradient and carbon dioxide elimination
- Bleeding events [ Time Frame: 30 days ]Will be assessed by the total number of one or more of the following: Chest tube output of blood, number of take-backs to operating room for bleeding, number of Hemorrhagic strokes, Gastrointestinal bleeding, Retroperitoneal hemorrhage, number of cessations of anticoagulation for refractory bleeding and any use of antifibrinolytics or factor VII
- Renal failure [ Time Frame: 30 days ]Defined as initiation of renal replacement therapy for kidney injury that develops on ECMO or increase in serum creatinine by more than 2 times its baseline or decrease in Glomerular Filtration Rate by more than 50% or urine output less than 0.3 mL/kg/hr. We will determine the number of patients with renal failure
- Number of Transfusions [ Time Frame: 30 days ]This will be assessed by any of the following: number of utilizations of packed red blood cells and utilization of fresh frozen plasma, utilization of platelets, utilization of cryoprecipitate, utilization of anti-thrombin III, utilization of factor VII, utilization of prothrombin complex concentrate
- Number of emergent decannulations [ Time Frame: 30 days ]This will be assessed by the number of times patient is separated from ECMO
- Number of patients surviving to discharge [ Time Frame: 30 days ]This will be assessed by the number of patients in each arm who survive to discharge

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult patients on veno-arterial (VA) or veno-venous (VV)ECMO
Exclusion Criteria:
- Patient or surrogate decision makers cannot provide informed consent.
- Patients who have intolerance to either heparin or bivalirudin
- Patients who received any form of thrombolytic therapy within the past 30 days.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03707418
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States, 21287 |
Principal Investigator: | Glenn Whitman, M.D. | Johns Hopkins University |
Responsible Party: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT03707418 |
Other Study ID Numbers: |
IRB00176475 |
First Posted: | October 16, 2018 Key Record Dates |
Last Update Posted: | January 19, 2021 |
Last Verified: | April 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Heparin Calcium heparin Bivalirudin Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents |
Molecular Mechanisms of Pharmacological Action Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors |